Cargando…

Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial

BACKGROUND: Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received complementary and alternative medicine. Traditional Chinese herbal formula is widely used in Asia, and clinical stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Lijiang, Zhao, Xiaoying, Zhang, Yuyan, Zhao, Ping, Gong, Rui, Li, Fang, Huang, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896428/
https://www.ncbi.nlm.nih.gov/pubmed/35244043
http://dx.doi.org/10.1097/MD.0000000000028895
_version_ 1784663161669943296
author Ji, Lijiang
Zhao, Xiaoying
Zhang, Yuyan
Zhao, Ping
Gong, Rui
Li, Fang
Huang, Hua
author_facet Ji, Lijiang
Zhao, Xiaoying
Zhang, Yuyan
Zhao, Ping
Gong, Rui
Li, Fang
Huang, Hua
author_sort Ji, Lijiang
collection PubMed
description BACKGROUND: Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received complementary and alternative medicine. Traditional Chinese herbal formula is widely used in Asia, and clinical studies have also found that Chinese herbal formula could significantly improve abdominal pain and diarrhea. We plan to carry out a randomized, controlled, double blind, clinical studies to observe the clinical efficacy of Qinghua Zhixie decoction in the treatment of D-IBS. METHODS: Four hundred sixty-four participants will be randomly assigned to the treatment group and control group. Patients in both groups would take medications and stimulations simultaneously. The outcomes of IBS symptom severity score, quality of life, psychological states, and recurrence rate will be recorded. Statistics will be analyzed with the SPSS 22.0. CONCLUSIONS: The findings of the study will identify the safety and efficacy of Qinghua Zhixie decoction in the treatment of D-IBS. TRIAL REGISTRATION: OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/C8MHW.
format Online
Article
Text
id pubmed-8896428
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-88964282022-03-07 Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial Ji, Lijiang Zhao, Xiaoying Zhang, Yuyan Zhao, Ping Gong, Rui Li, Fang Huang, Hua Medicine (Baltimore) 3800 BACKGROUND: Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received complementary and alternative medicine. Traditional Chinese herbal formula is widely used in Asia, and clinical studies have also found that Chinese herbal formula could significantly improve abdominal pain and diarrhea. We plan to carry out a randomized, controlled, double blind, clinical studies to observe the clinical efficacy of Qinghua Zhixie decoction in the treatment of D-IBS. METHODS: Four hundred sixty-four participants will be randomly assigned to the treatment group and control group. Patients in both groups would take medications and stimulations simultaneously. The outcomes of IBS symptom severity score, quality of life, psychological states, and recurrence rate will be recorded. Statistics will be analyzed with the SPSS 22.0. CONCLUSIONS: The findings of the study will identify the safety and efficacy of Qinghua Zhixie decoction in the treatment of D-IBS. TRIAL REGISTRATION: OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/C8MHW. Lippincott Williams & Wilkins 2022-03-04 /pmc/articles/PMC8896428/ /pubmed/35244043 http://dx.doi.org/10.1097/MD.0000000000028895 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 3800
Ji, Lijiang
Zhao, Xiaoying
Zhang, Yuyan
Zhao, Ping
Gong, Rui
Li, Fang
Huang, Hua
Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial
title Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial
title_full Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial
title_fullStr Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial
title_full_unstemmed Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial
title_short Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial
title_sort efficacy and safety of qinghua zhixie decoction against diarrhea-predominate irritable bowel syndrome: a protocol for a randomized controlled trial
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896428/
https://www.ncbi.nlm.nih.gov/pubmed/35244043
http://dx.doi.org/10.1097/MD.0000000000028895
work_keys_str_mv AT jilijiang efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial
AT zhaoxiaoying efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial
AT zhangyuyan efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial
AT zhaoping efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial
AT gongrui efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial
AT lifang efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial
AT huanghua efficacyandsafetyofqinghuazhixiedecoctionagainstdiarrheapredominateirritablebowelsyndromeaprotocolforarandomizedcontrolledtrial